Dr. Clay Seigall is the Co-Founder and CEO of Seattle Genetics. He also enjoys finding interesting articles online and sharing them on his official blog. A recent one he shared was about the learning myths that people have and a quiz to see if you hold them. In the article, experts talk about how most people are ignorant of research on learning. One of the key points of the article is that 90% of people think students should learn information in their own “learning” style. Research into learning actually says, even though that sounds intuitive, it’s completely wrong according to research.
Another article that Dr. Siegall posted is a new, better way to clean up oil spills. The article describes an invention, called the Flame Refluxer, is actually quite simple and incorporates copper wool, in between layers of thin copper, with copper coils attached to the top. The device is put over an oil spill and it’s set on fire; the coils collect the heat and the device dissipate it which leads to a complete burn of the spill.
Dr. Seigall founded Seattle Genetics in 1998 after several years of research and development into drugs that treat cancer. The first drug that he developed at Seattle Genetics that was approved by the FDA is Adcetris which treats several forms of Lymphoma. His company also has several anti-cancer drugs in the pipeline at various stages of development. He also announced in 2016 that he has ambitious plans as he seeks to develop 12 more drugs and hire more than a hundred people.
Under Dr. Seigall’s leadership, Seattle Genetics has grown into a company that already has more than 800 employees. Besides the headquarters of the company in Bothell, Washington, it also has an office in Switzerland that opened in 2016. Their drug Adcetris achieved sales of $226 million in 2015 and was on pace for sales of $255 to $275 million for 2016.
In addition to his work at Seattle Genetics, Dr. Seigall plays a larger role in the cancer research community. He sits on the board of several pharmaceutical companies including Alder BioPharmaceuticals and Mirna Therapeutics.